Epanova: Phase III data

Additional data from the double-blind, international Phase III EVOLVE trial in 399 patients with triglyceride levels of 500-2,000 mg/dL showed that once-daily 2 and 4 g Epanova non-significantly increased mean HDL-C from baseline to week 12 vs. control (4 g olive oil) (8% and 6%, respectively, vs. 2%). Low- and high dose Epanova did significantly reduce several markers of atherogenicity, including apolipoprotein C-III ( APOCIII; APOC3) and lipoprotein-associated phospholipase A2 ( PLA2G7; PAFAH; Lp-PLA2), vs. control. Data for the once-daily 3 g dose of Epanova were not disclosed. ...